Market Newsdesk

DENVER, Sept. 28, 2026 (GLOBE NEWSWIRE) — (247marketnews.com) — NeOnc Technologies Holdings (NASDAQ: NTHI) is putting another major date on the biotech calendar: November 17, 2026, when the company is scheduled to meet with the U.S. Food and Drug Administration for an in-person End-of-Phase 1 Type B meeting covering its experimental brain-cancer drug NEO212.

The meeting could become an important inflection point for a company that has rapidly assembled a string of clinical, regulatory and Wall Street catalysts.

NeOnc says it plans to seek FDA feedback on NEO212’s proposed patient population, trial design, endpoints, dose selection and the evidence that could ultimately support a marketing application. The company also intends to discuss a potential registrational strategy and whether a proposed Phase 2 design could potentially support an accelerated-approval pathway; marking a meaningful transition from dose-finding toward the next stage of clinical development.

NEO212 enters that meeting with some intriguing, though still preliminary, human data.

During Phase 1, dose escalation reached the protocol-defined maximum tolerated dose at 810 mg, after which the recommended Phase 2 dose was established at 610 mg. The company has highlighted a patient with recurrent IDH1 wild-type, MGMT-methylated glioblastoma who experienced an approximately 60% tumor reduction and 21 months of disease control. Another heavily pretreated patient with lung cancer metastatic to the brain experienced stable disease for approximately 16 months. These are individual patient observations, not proof of efficacy, and larger trials will have to determine whether the results can be replicated.

NeOnc CEO Amir Heshmatpour put the immediate objective plainly: “This meeting will help us understand FDA’s feedback on the population, study design and endpoints for the next stage of development.”

The NEO212 catalyst arrives as the broader NeOnc story is also attracting Wall Street attention. Roth Capital recently initiated coverage of NeOnc with a $20 price target, with analyst Jonathan Aschoff reportedly anticipating potential pivotal-trial starts by the end of 2026.

NeOnc is now advancing two potential therapies in its CNS cancer pipeline, giving investors more than one clinical catalyst to watch. Its lead program, NEO100, recently generated topline Phase 2a data in recurrent IDH1-mutant high-grade glioma, with the company reporting six-month progression-free survival of 48.9% versus a prespecified 20% benchmark and median overall survival of 26.09 months. NeOnc said it plans to engage with the FDA regarding a potential registrational pathway.

The parallel development tracks could give NeOnc multiple potential catalysts heading into 2027. Roth Capital’s research indicates Aschoff expects an FDA Type B End-of-Phase 2 meeting for NEO100 in October and sees potential pivotal-trial starts before the end of 2026.

Meanwhile, NeOnc has raised capital from institutional investors, including a September registered direct offering priced at $4.20 per share and accompanying warrants. Company insiders have also been active buyers: SEC filings show recent open-market purchases by executives including Heshmatpour and Thomas C. Chen.

That backdrop makes November 17 particularly interesting. NTHI is approaching the FDA with a defined Phase 2 dose, early signals of clinical activity and a stated ambition to develop NEO212 across difficult-to-treat CNS cancers.

If the agency provides a workable path forward on population, endpoints and study design, NEO212 could emerge from the meeting with a substantially clearer development roadmap.

For NTHI shareholders, November 17 is therefore less about expecting an approval and more about watching whether the FDA conversation turns NEO212 from an intriguing clinical program into a more clearly defined late-stage development story.

About 24/7 Market News

In today’s fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you’re an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact [email protected] to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.

PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.

Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.

CONTACT:

24/7 Market News
[email protected]

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.

KUALA LUMPUR, Malaysia, Sept. 28, 2026 (GLOBE NEWSWIRE) — Treasure Global Inc. (NASDAQ: TGL) (“Treasure Global” or the “Company”), a Southeast Asia–anchored technology company focused on AI-powered enterprise solutions and digital transformation, today announced that it has signed a non-binding memorandum of understanding (“MOU”) with Mestiz Holding Berhad (“MHB”) for the proposed US$38 million cash acquisition of a 51% controlling interest in Mestiz Century Logic Sdn Bhd (“MCL”), a Malaysia-based provider of cloud-based smart water metering technology and digital water management solutions.

Under the MOU, MHB has granted Treasure Global a 120-day exclusivity period to conduct due diligence on MCL and negotiate the terms of a definitive agreement. Completion of the proposed acquisition remains subject to the execution of a definitive agreement and customary closing conditions, including satisfactory completion of due diligence and receipt of required regulatory and board approvals.

MCL specializes in smart water metering solutions powered by cloud computing and Internet of Things (“IoT”) technology. Its smart meters are designed to deliver up to four times the accuracy of conventional mechanical meters, while providing enhanced durability and digital connectivity.

MCL’s smart metering platform further integrates artificial intelligence to support real-time consumption monitoring, remote meter reading, leak detection and predictive maintenance, enabling utilities to improve operational visibility and transition toward more intelligent, data-driven water management.

“Smart water metering represents a significant diversification opportunity for Treasure Global,” said Sam Teo, Acting Chief Executive Officer of Treasure Global. “MCL’s cloud-based, IoT and AI-enabled technology addresses a growing need among utilities to modernize aging water infrastructure, improve billing accuracy and reduce water loss. We believe intelligent metering, real-time data and predictive analytics can create meaningful operational value while supporting more efficient and data-driven water management.”

The proposed acquisition comes amid continued global growth in smart water infrastructure. According to Fortune Business Insights, the global smart water meter market is estimated at approximately US$6.02 billion in 2026 and is projected to reach approximately US$14.74 billion by 2034, representing a compound annual growth rate of approximately 11.85% over the forecast period.

If completed, the proposed acquisition would mark Treasure Global’s entry into the smart utility infrastructure sector, expanding the Company’s technology portfolio beyond digital payments and enterprise AI. The transaction would provide Treasure Global with exposure to a growing smart-metering market while supporting its strategy of building diversified, technology-driven revenue streams and long-term shareholder value.

About Treasure Global:

Treasure Global is a Malaysia-based technology solutions provider specializing in innovative platforms that drive digital transformation in retail and services. The Company’s flagship product is the ZCITY Super App, which integrates e-payment solutions with customer loyalty rewards to create a seamless online-to-offline user experience. As of March 31, 2026, ZCITY has attracted 2.71 million registered users, positioning Treasure Global as a key player in Malaysia’s digital economy. Treasure Global continuously leverages cutting-edge technologies, including artificial intelligence and data analytics, to enhance its platform’s capabilities across e-commerce, fintech, and other verticals.

Visit treasureglobal.org for more information.

Forward-Looking Statements


This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements reflect the Company’s current expectations, assumptions, and projections about future events and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking statements typically include terminology such as “anticipates,” “believes,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” or similar expressions.

Factors that could cause actual results to differ materially include, without limitation, the parties’ ability to negotiate and execute a definitive agreement; satisfactory completion of due diligence; completion of the proposed acquisition; the Company’s ability to integrate MCL and realize anticipated strategic benefits; adoption and performance of MCL’s smart water metering technology; customer and utility demand; regulatory and procurement requirements; technology performance; cybersecurity and data privacy risks; competition; and changes in economic, infrastructure and market conditions.

The forward-looking statements in this press release speak only as of the date hereof. The Company assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

CONTACT

Investor and media contact:

Investor Relations Team
Treasure Global
[email protected]

NEW YORK, Sept. 28, 2026 (GLOBE NEWSWIRE) — FN MediaNews Commentary – Governments are on an arms and domestic security buying spree as traditional air defense systems are being replaced by layered networks that can detect, identify, track, and neutralize a large number of low-cost drones. Fortune Business Insights estimates the global counter-UAS market will grow from $14.41 billion in 2026 to $55.25 billion in 2034, at a CAGR of 22.4%. Likewise, MarketsandMarkets estimates the global C-UAS market will grow from $6.6 billion in 2025 to $20.3 billion in 2030, and the US market will reach $8.60 billion by 2030 from $2.49 billion in 2025. This isn’t limited to the battlefield. Much of this investment is focused on military bases, airports, borders, power grids, government facilities, stadiums, and other sensitive sites that require autonomous or semi-autonomous systems that respond faster than human operators can track, classify, and deploy countermeasures. It represents a massive opportunity for firms offering scalable solutions that incorporate radar, RF, electro-optical sensors, AI-enabled threat classification, electronic warfare, directed energy, and interceptor drones in a single system. Demand for advanced counter-drone technology has accelerated at a massive pace presenting opportunity for active companies in the Drone/UAV industries that may include Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO), Red Cat Holdings, Inc. (NASDAQ: RCAT), Unusual Machines, Inc. (NYSE American: UMAC), Ondas Inc. (NASDAQ: ONDS), Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS).

Meanwhile, the competition to become more self-defending is turning the tables on what the systems of the future will look like: not only can software and AI and autonomous systems be used to control a range of platforms than currently have to be manually controlled, but they can also be used to coordinate operations. Recent US Army exercises reportedly brought 1,900 autonomous systems, and the Pentagon has already earmarked 1 billion to buy at least 200,000 drones by 2027 – signposts that we’re now very much in a world of swarms of relatively cheap unmanned systems. The US Air Force is reportedly set to order more than 150 semi-autonomous Collaborative Combat Aircraft, evidence of a trend of autonomy moving from an experimental technology to an organizational structure for the military. Today’s systems are no longer just radars and jammers, but networks of systems that use AI not only to detect and analyze threats but prioritize and deploy a defense response across multiple systems. Investors should take note of the fact that the worlds of counter-drone tech and autonomous defense are rapidly converging.

Key Market Catalysts for the industry:

• $55.25 billion: Fortune Business Insights’ projected global Counter-UAS market by 2034.
• $20.3 billion: MarketsandMarkets’ projected global C-UAS market by 2030.
• $8.60 billion: Projected U.S. C-UAS market by 2030, compared with $2.49 billion in 2025.
• $30.03 billion: Value Market Research’s 2034 projection for the global counter-drone market.
• AI + autonomy: AI-enabled detection, autonomous threat response, interceptor drones, electronic warfare and layered defense are emerging as core components of next-generation C-UAS architectures.

Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO)
Announces Strategic Investment from Unusual Machines and a Leading U.S. Investment Fund – Unusual Machines (NYSE American: UMAC) and a leading U.S. Investment Fund make a strategic investment of $10M, each investing $5M into Draganfly, in support of the Company’s growing position in the U.S. defense ecosystem while also gaining access to strategic opportunities in international markets uniquely served by Draganfly. – Draganfly Inc. (FSE: 3U8A) (“Draganfly” or the “Company”), an industry-leading developer of drone solutions, systems and technologies, announces a US$10 million strategic investment by Unusual Machines, Inc. (NYSE American: UMAC) and a leading U.S. Investment Fund, each investing $5M (the “Investment”).

This strategic investment comes during a period of accelerating commercial and defense activity for Draganfly across both the United States and Canada, including significant recent procurement milestones with the Canadian Armed Forces and continued important expansion of the Company’s U.S. defense operations. Draganfly intends to use the net proceeds to accelerate the development of advanced strategic capabilities and to fund general working capital in meeting demand for its products in the rapidly maturing U.S. and international markets.

“We are seeing the convergence of customer adoption, government procurement, domestic manufacturing, defense autonomy and strategic industry participation,” said Cameron Chell, CEO and Chairman of Draganfly. “This strategic investment from Unusual Machines and a leading U.S. Investment Fund is about positioning, not size. It is about aligning capabilities that can best serve the industries’ requirements at scale domestically and abroad.”

“America and its allies are entering a period in which the ability to manufacture drones, components and autonomous systems at scale is becoming a strategic capability,” said Dr. Allan Evans, CEO of Unusual Machines. “This investment into Draganfly allows us to support their production growth and deepen our supplier relationships.” The Investment is priced at-market based on the closing price of the Company’s common shares on Friday, September 25, 2026, and represents an important step in the maturation of the US and international drone supply chain and ecosystem.

The Investment is a registered direct offering to purchase 1,869,159 common shares of the Company at a price of US$5.35, for gross proceeds of approximately US$10 million, before deducting placement agent discounts and offering expenses. Jett Capital Advisors, LLC and Northland Capital Markets are acting as joint-lead placement agents in the offering. The Investment is expected to close on or about September 29, 2026, subject to the satisfaction of customary closing conditions, including receipt of all necessary regulatory approvals, including approval of the Canadian Securities Exchange and notification to the Nasdaq Stock Market.

The Investment is being made pursuant to an effective shelf registration statement on Form F-10, as amended (File No. 333-290823), previously filed with and subsequently declared effective by the U.S. Securities and Exchange Commission (“SEC”) on February 25, 2026, and the Company’s Canadian short form base shelf prospectus dated October 24, 2025 (the “Base Shelf Prospectus”). Draganfly will offer and sell the securities in the United States only. No securities will be offered or sold to Canadian purchasers.

A prospectus supplement and accompanying Base Shelf Prospectus relating to the Investment and describing the terms thereof will be filed with the applicable securities commissions in Canada and with the SEC in the United States and will be available for free by visiting the Company’s profiles on the SEDAR+ website maintained by the Canadian Securities Administrators at www.sedarplus.ca or the SEC’s website at www.sec.gov, as applicable. Copies of the prospectus supplement and accompanying Base Shelf Prospectus relating to the Investment may be obtained, when available, by contacting Jett Capital Advisors, LLC, at 712 Fifth Ave, 11th Floor, New York, NY 10019, Attention: General Inquiries, or by telephone at +1-212-616-0430 or by email at [email protected], or Northland Securities, Inc., at 150 South Fifth Street, Suite 3300, Minneapolis, MN 55402, Attention: Valencia Day, or by telephone at +1-612-851-4917, or by email at [email protected]. Continued…Read this full release and additional news for DPRO by visiting: https://draganfly.com/news/

Drone and UAS breakthroughs are fueling explosive growth across defense, autonomy, surveillance, and battlefield technology for companies including:

Unusual Machines, Inc. (NYSE American: UMAC), a leading manufacturer of NDAA-compliant drone components, recently announced an additional $20 million strategic investment in XTEND AI Robotics Inc. (XTND), a Physical AI company and existing Unusual Machines customer. The additional $20 million brings Unusual Machines’ total investment in XTEND to $27.5 million and is part of, and not in addition to, the $110 million financing, which closed in connection with XTEND’s business combination and NYSE listing.

The investment reflects Unusual Machines’ broader approach to deploying capital across the drone ecosystem and into technologies and companies that complement its core component business.

“We believe drones are part of a much bigger shift toward autonomous systems and robotics,” said Allan Evans, Chief Executive Officer of Unusual Machines. “When we look at strategic investments, we look for companies that are expanding what unmanned systems can do, demonstrating an ability to execute, and investing in the U.S. industrial base. XTEND is doing all three very well. We believe they have an important role to play in where the industry is headed.”

Red Cat Holdings, Inc. (NASDAQ: RCAT), a U.S. based provider of advanced all domain drone and robotic solutions for defense and national security, announced that its Blue Ops maritime division marked the inaugural Blue Ops Day on September 21 with a celebration at the company’s manufacturing facility in Valdosta, Georgia.

Recognized through proclamations from the State of Georgia and Valdosta-Lowndes County, Blue Ops Day marked the culmination of a year of significant growth for Blue Ops in Georgia. Since leasing its 155,000-square-foot Valdosta facility in September 2025, Blue Ops has expanded its domestic manufacturing capabilities, announced plans to invest $30 million and create more than 200 local jobs, added advanced manufacturing technologies, and begun ramping its Variant 7 Uncrewed Surface Vessel (USV) into full-rate production.

The event recognized that progress with a celebration at the Valdosta facility, where Blue Ops has spent the past year building out the team, technology and infrastructure needed to support U.S. production of its growing family of USVs. Red Cat and Blue Ops leadership were joined by elected officials, employees and community leaders to recognize the milestone and Blue Ops’ growing role in Georgia and the U.S. maritime industrial base.

Ondas Inc. (NASDAQ: ONDS), a leading provider of autonomous systems and next-generation defense and security technologies, announced recently that it has acquired three defense technology businesses, adding advanced capabilities that enhance the Company’s mission capabilities and expand its addressable markets. The acquired businesses bring technologies ranging from systems already deployed in active conflict environments to capabilities positioned for near-term mission integration across Ondas’ existing platforms. The acquisitions are designed to strengthen Ondas’ existing and future autonomous platforms, accelerate the development of integrated solutions and create new opportunities for growth across the defense and autonomous systems markets. 

“These acquisitions reflect our strategy of assembling the critical technologies required to make autonomous systems more capable, resilient and scalable in contested environments,” said Eric Brock, Chairman and CEO of Ondas Inc. “Together, these businesses give Ondas more to sell and more ways to win. They add commercial revenue streams we can grow across our customer base, and they strengthen our ability to pursue larger, longer-term customer programs where we deploy and sustain more capable autonomous systems on behalf of the customers we serve.”

Kratos Defense & Security Solutions, Inc., (NASDAQ: KTOS), a technology company in the defense, national security and global markets, and GE Aerospace (GE) announced a key program milestone with the successful ignition of the GEK800 turbofan cruise missile propulsion system. Recently, the GEK800 Serial Number 1 was tested at the X-58 test facility, igniting successfully. This achievement initiates a new testing campaign and demonstrates a 100 percent success rate for this critical phase of development, keeping the program on schedule.

Recently designated the F143 and designed to meet the defined requirements of the Department of War for long-range, stand-off strike capabilities, the GEK800 represents a significant advancement in affordable, high-performance cruise missile technology. By leveraging modern engineering and cost-effective manufacturing processes, Kratos and GE Aerospaceare positioned to deliver substantial capability and value to the warfighter.

DISCLAIMER: FN Media (FNM) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM’S market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM expects to be compensated forty eight hundred dollars for news coverage of the current press releases issued by Draganfly Inc. by a non-affiliated third party. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:

Media Contact email: [email protected] – +1(561)486-1799

SOURCE: FN Media Group

NEW YORK, Sept. 28, 2026 (GLOBE NEWSWIRE) — Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against DICK’s Sporting Goods, Inc. (“Dick’s Sporting Goods” or the “Company”) (NYSE: DKS) on behalf of investors that purchased or otherwise acquired Dick’s Sporting Goods common stock between September 8, 2025 and August 24, 2026 (the “Class Period”).

CLICK HERE TO JOIN THE CASE

If you are an investor in Dick’s Sporting Goods and have suffered losses, you may


CLICK HERE


to contact us. You may also contact Kaplan Fox by emailing


[email protected]


or by calling (646) 315-9003.

DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than November 3, 2026 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.

On September 8, 2025, the first day of the Class Period, Dick’s Sporting Goods announced the completion of its acquisition of Foot Locker, Inc. (“Foot Locker”) for approximately $2.5 billion in cash and stock.

The complaint alleges that throughout the Class Period, Defendants misled investors regarding the Company’s acquisition of Foot Locker, touting the acquisition as a strategic opportunity to drive growth and profitability while assuring investors that Foot Locker’s longstanding inventory and promotional challenges had been resolved. In reality, according to the complaint, those problems persisted, as Foot Locker remained heavily dependent on legacy footwear products that were exposed to intensifying promotional pressures across the athletic footwear industry.

The truth was allegedly revealed to investors before markets opened on August 25, 2026, when Dick’s Sporting Goods reported disappointing second-quarter 2026 results, which included revenue of $1.73 billion from Foot Locker that fell well short of analysts’ estimates of $1.81 billion. Dick’s Sporting Goods also reduced its net sales guidance for full-year 2026 and disclosed that it expected Foot Locker’s proforma comparable sales to yield a range of negative 2.0% to 0.0% for the year—down from Dick’s prior forecast of 1.5% to 3% growth.

On this news, the price of Dick’s Sporting Goods stock fell $55.02 per share, or 30.68%, to close at $124.31 per share on August 25, 2026.

WHY CONTACT KAPLAN FOX?

Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.

Kaplan Fox is widely regarded as one of the nation’s premier plaintiffs’ securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America—the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act—$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch.

For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.

If you have any questions about this Notice, your rights, or your interests, please contact:

CONTACT:

Pamela A. Mayer
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York 10022
(646) 315-9003
[email protected]

Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1501
Oakland, California 94612
(415) 772-4704
[email protected]

Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.

https://www.kaplanfox.com/case/dicks-sporting-goods-inc-class-action-lawsuit-learn-more-now/

NEW YORK, Sept. 28, 2026 (GLOBE NEWSWIRE) — Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) on behalf of investors that purchased or otherwise acquired Beta Bionics common stock between July 30, 2025 and February 24, 2026 (the “Class Period”).

CLICK HERE TO JOIN THE CASE

If you are an investor in Beta Bionics and have suffered losses, you may


CLICK HERE


to contact us. You may also contact Kaplan Fox by emailing


[email protected]


or by calling (646) 315-9003.

DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than November 3, 2026 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.

Beta Bionics is a commercial-stage medical device company, serving patients with diabetes through the iLet Bionic Pancreas insulin pump (“iLet”), an automated insulin delivery system. The complaint alleges that throughout the Class Period, Beta Bionics received thousands of complaints from iLet customers, including numerous reports of serious, life-threatening hypoglycemia caused by device malfunctions that required hospitalization to treat. The root cause of these malfunctions was allegedly iLet’s extremely aggressive dosing algorithm.

The truth was allegedly revealed through a series of disclosures starting on January 8, 2026 when Beta Bionics surprised investors with a miss on the key metric of new iLet patient starts, which was followed by a 37% one-day stock price decline. Finally, on February 24, 2026, the full truth was allegedly revealed when the U.S. Food and Drug Administration (the “FDA”) publicly released its warning letter detailing a litany of violations and Defendants’ failure to correct them, and contradicting months of Defendants’ public statements that all back-filed complaints were for entirely benign issues. According to the complaint, the warning letter made clear that Defendants’ prior interpretation of FDA reporting requirements had not been reasonable, and had excluded numerous serious patient incidents that clearly should have been reported.

WHY CONTACT KAPLAN FOX?

Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.

Kaplan Fox is widely regarded as one of the nation’s premier plaintiffs’ securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America—the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act—$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch.

For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.

If you have any questions about this Notice, your rights, or your interests, please contact:

CONTACT:

Pamela A. Mayer
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York 10022
(646) 315-9003
[email protected]

Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1501
Oakland, California 94612
(415) 772-4704
[email protected]

Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.

https://www.kaplanfox.com/case/beta-bionics-nasdaq-bbnx-class-action-lawsuit-learn-more-now/

• Expansion benefits families, remote work, gaming, streaming, agriculture, telehealth
• In celebration, Kinetic to host free community festivities Sept. 28 – Oct. 5

CHARLOTTE, N.C., Sept. 28, 2026 (GLOBE NEWSWIRE) — Kinetic, the leading residential and business insurgent fiber internet provider, announced today that it increased its fiber network in the greater Concord area by nearly 23% in the last year.

Kinetic added more than 7,800 new fiber locations in the community, surpassing a major milestone of more than 38,000 homes passed. This expansion is fully funded by Kinetic and highlights the company’s commitment to this community and is a signal of future growth and opportunity across the region.

“Concord is a key market for Kinetic and an important link in the region’s growing technology corridor,” said Stacy Hale, Kinetic’s state operations president. “In honor of surpassing this milestone, it’s time that we celebrate. And to the residents of this area, know that we’re not done yet; we’ll continue adding more fiber locations and will remain a long-term partner to this community.”

Fast Forward

: Concord — a Free Community Celebration

To celebrate this milestone, Kinetic will host a week of free events for the community.

Planned week highlights

• Tuesday, Sept. 29: Kinetic employees will volunteer at the Sonshine Backpack Ministry, a nonprofit program that provides weekly food bags to school aged children that face food insecurities.
• Thursday, Oct. 1: Kinetic will host a free technology, internet and security course from 10:30 – 11:15 a.m. at the Kannapolis VFW Post 8989 for those who need a more hands-on experience with tech.  
• Friday, Oct. 2: Concord Fiber Night Lights, where Kinetic will give away swag items at the Central Cabarrus vs Cox Mills high school football game starting at 7 p.m. While supplies last.
• Saturday, Oct. 3: Kinetic will have a booth at the Concord International Festival in Downtown Concord from noon to 6 p.m. Stop by for family fun and free swag items.

Why Kinetic’s fiber infrastructure matters
to North Carolina

Fiber is the best technology for the long-term success of Concord’s communications needs. Research shows that fiber-connected communities experience 213% higher business growth, 10% higher self-employment and a potential 14-17% increase in home values. Fiber is also significantly more sustainable than copper and uses up to 95% less energy per gigabit. It requires less maintenance over time, which reduces environmental impact and community disruption.

As a long-term partner to the Concord community, Kinetic Is committed to delivering on its promise to provide fast, reliable, future-proof connectivity that helps local economic growth, education, telehealth, and small business competitiveness. This investment underscores the company’s dedication to providing the communities it serves—the same communities its employees also live and work in—with sustained value both now and for years to come.

Kinetic, which was also named CNET’s Best Rural Fiber Internet Provider in 2026, is rooted in North Carolina and is proud to serve its communities beyond internet connectivity. Kinetic’s fiber expansion milestone in Concord follows the company recently reaching 2 million homes passed with fiber internet across its 18-state footprint.

Residents who want to check fiber availability or construction updates can call 1- 877-90-FIBER (877-903-4237) or visit www.gokinetic.com.

About Kinetic: Named the 2026 Telecommunications Company of the Year (Stevie GOLD/American Business Awards), Kinetic is a business unit of Uniti (NASDAQ: UNIT), and is a premier insurgent provider of multi-gigabit fiber internet, whole-home Wi-Fi, internet security, and voice services in 1,400 markets across 18 states in the Southwestern, Southeastern, Midwestern, and Northeastern U.S. Additional information is available at gokinetic.com.

Media Contact

Victoria Carman
[email protected]

Substantially all planned REO 033 clinical sites are now activated, with multiple patients currently on study

Company expects to have sufficient Part A data to provide an interim clinical update by year-end 2026

FDA alignment provides potential path to accelerated approval based on objective response rate and full approval based on progression-free survival

SAN DIEGO, Sept. 28, 2026 (GLOBE NEWSWIRE) — Oncolytics Biotech^® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced continued clinical and operational progress in REO 033, its randomized study evaluating pelareorep in second-line RAS-mutant, microsatellite-stable (“MSS”) metastatic colorectal cancer (“mCRC”).

Nearly all planned clinical sites for Part A of REO 033 have now been activated, and multiple patients are currently enrolled (link to study on ClinicalTrials.gov). With the site activation process largely complete, the Company is focused on accelerating enrollment and generating randomized clinical data evaluating the contribution of pelareorep to the current standard-of-care regimen.

REO 033 is a randomized controlled study evaluating pelareorep in combination with folinic acid, fluorouracil and irinotecan (“FOLFIRI”) and bevacizumab versus FOLFIRI and bevacizumab in patients with second-line RAS-mutant MSS mCRC. Part A is expected to enroll approximately 60 patients randomized between the two treatment arms, with objective response rate (“ORR”) as the primary endpoint, and progression-free survival (“PFS”), overall survival (“OS”), safety, and biomarker analyses among the additional endpoints.

“We are seeing strong momentum in REO 033 now that substantially all of our planned sites are open and multiple patients are on study,” said John McAdory, Chief Operating Officer of Oncolytics. “Given the current pace of enrollment, we expect to have the ability to report interim data from Part A by year-end, based on the number of evaluable patients enrolled by the end of October. Importantly, with site activation substantially behind us, our focus is now squarely on enrollment, execution, and generating the randomized clinical data that can inform the next stage of the program.”

REO 033 Builds on Encouraging REO 022 Clinical Data

REO 033 was designed to prospectively evaluate the efficacy signals previously observed in REO 022 in a randomized setting. In REO 022, pelareorep in combination with FOLFIRI and bevacizumab demonstrated encouraging ORR, PFS, and OS compared with historical second-line benchmarks:

Efficacy Measure	REO 022: Pelareorep + FOLFIRI + Bevacizumab 1	Historical Second-Line Benchmark
Objective Response Rate	33 %	~6–11%2, 3
Median Progression-Free Survival	16.6 months	~5.7 months2
Median Overall Survival	27.0 months	~11.2 months2
Median Duration of Response	19.5 months	~4–6 months4

The REO 022 results were generated in a small, non-randomized study, and cross-study comparisons have inherent limitations. REO 033 is designed to test the pelareorep regimen prospectively against a concurrent control arm and determine whether the efficacy signals observed in REO 022 can be replicated in a randomized study.

Potential Registration Path Aligned with the Food and Drug Administration

The Company recently aligned with the U.S. Food and Drug Administration (the “FDA”) on the concept for a potential pivotal Part B expansion of REO 033.

Under the proposed regulatory strategy, Part B would build directly upon the ongoing randomized REO 033 study and could support a potential accelerated approval submission based on objective response rate, with progression-free survival providing the basis for potential full approval.

The Company expects data from Part A to inform the final size and execution of the potential pivotal Part B expansion.

About Pelareorep

Pelareorep is an intravenously delivered, systemically active, investigational immunotherapy with a dual mechanism of action that selectively replicates in tumor cells while activating both innate and adaptive anti-tumor immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes. It has been administered to over 1,200 patients, and clinical studies have demonstrated pelareorep’s potential to enhance the activity of checkpoint inhibitors and other anti-cancer therapies across multiple solid tumor types.

About Oncolytics Biotech Inc.

Oncolytics is a clinical-stage biotechnology company developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent. Pelareorep has demonstrated encouraging results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer, and early-phase studies in anal and colorectal cancer. It is designed to induce anti-cancer immune responses by converting immunologically inactive tumors to active through the activation of innate and adaptive immune responses.

The Company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors in metastatic gastrointestinal cancers, where pelareorep has received Fast Track designation from the FDA for colorectal, anal, and pancreatic cancer. Oncolytics is actively pursuing strategic partnerships to accelerate development and maximize commercial impact. For more about Oncolytics, please visit: www.oncolyticsbiotech.com or follow the Company on LinkedIn and on X @oncolytics.

References

1. Goel S, et al. Elucidation of Pelareorep Pharmacodynamics in A Phase I Trial in Patients with KRAS-Mutated Colorectal Cancer. Mol Cancer Ther. 2020 May;19(5):1148-1156. doi: 10.1158/1535-7163.MCT-19-1117.
2. Bennouna J. Lancet Oncol (14):29-37, 2013
3. Iwamoto S. Ann Oncol. Jul;26(7):1427-33, 2015
4. FDA grants accelerated approval to adagrasib with cetuximab for KRAS G12C–mutated colorectal cancer. Published June 21, 2024. Accessed April 28, 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-adagrasib-cetuximab-kras-g12c-mutated-colorectal-cancer

Forward-looking statements

This press release contains forward-looking statements, within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as “forward-looking statements”). Forward-looking statements contained in this press release include those regarding beliefs as to the potential, registration, mechanism of action and benefits of pelareorep as a cancer therapeutic; the Company’s goals, strategies, and objectives; expectations around the design, milestones, anticipated timelines and expected outcomes for current and future studies; the timeline and outcome of interim data from Part A of REO 033; the results of the proposed regulatory strategy and approval of Part B of REO 033; the Company’s belief in the clinical promise of pelareorep in anal, colorectal, pancreatic and other gastrointestinal cancers; and the Company’s goals and expectations for its potential registrational development path for pelareorep in multiple gastrointestinal cancers. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those anticipated. These risks include, but are not limited to, regulatory outcomes, trial execution, financial resources, access to capital markets, and market dynamics. Please refer to Oncolytics’ public filings with securities regulators in the United States and Canada for more information. The Company assumes no obligation to update forward-looking statements, except as required by law.

Company Contact

Jon Patton
Director of IR & Communication
[email protected]